Breaking News
Get 50% Off 0
🤫 Unfair Advantage: 10 bargain stocks found using this simple tool
See undervalued stocks

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
3 Things to Know About the Q4 Earnings Season By Zacks Investment Research - Jan 21, 2022

We get into the heart of the Q4 earnings season this week, with results from more than 300 companies coming out, including a total of 108 S&P 500 members.While the results thus far from the 12.8%...

New Strong Buy Stocks for January 21st By Zacks Investment Research - Jan 21, 2022

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ArcBest (NASDAQ:ARCB) ARCB: This company that provides freight transportation services and solutions has seen the Zacks...

Why Netflix (NFLX) Nosedived on Friday By Zacks Investment Research - Jan 21, 2022

Shares of streaming giant Netflix (NASDAQ:NFLX) NFLX closed down almost 22% on Friday as investors digested its latest quarterly earnings report. NFLX declined as much as 24% earlier in the...

MarketAxess (MKTX) Gears Up for Q4 Earnings: What to Expect By Zacks Investment Research - Jan 21, 2022

MarketAxess Holdings Inc. MKTX is set to report fourth-quarter 2021 results on Jan 26, before the opening bell.In the last reported quarter, the leading electronic trading platform operator reported...

Securities Exchanges Benefitting From Market Volatility By Zacks Investment Research - Jan 21, 2022

The recent trend of increased trading volume continued its ascent last year, as market data provider Statista reported that the total value of global equity trading soared to more than $37 trillion...

Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer By Zacks Investment Research - Jan 21, 2022

Amgen Inc (NASDAQ:AMGN). AMGN announced that the Japan Ministry of Health, Labour and Welfare has approved its KRAS inhibitor, Lumakras (sotorasib). The drug is now approved in Japan for the treatment...

Charles River (CRAI) Stock Up 44% in a Year: Here's Why By Zacks Investment Research - Jan 21, 2022

Shares of Charles River AssociatesCRAI have returned 44% over the past year, outperforming 34.7% growth of the industry it belongs to in the said time frame.Image Source: Zacks Investment...

Murphy Oil (MUR) to Report Q4 Earnings: What's in Store? By Zacks Investment Research - Jan 20, 2022

Murphy Oil Corporation (NYSE:MUR) MUR is slated to report fourth-quarter 2021 financial results on Jan 27, before the opening bell. The company has a trailing four-quarter earnings surprise of 83.61%,...

Walgreens (WBA), Village MD Plan to Expand Into Arizona By Zacks Investment Research - Jan 20, 2022

Walgreens Boots Alliance (NASDAQ:WBA), Inc. WBA and Village MD recently announced plans to open eight new Village Medical at Walgreens primary care and pharmacy practices in the Tucson area in 2022....

Why Apple Stock is a 'Strong Buy' Ahead of Earnings By Zacks Investment Research - Jan 20, 2022

Apple AAPL stock is down roughly 9% from its early January highs ahead of its first quarter fiscal 2022 financial release on Thursday, Jan. 27. The drop comes amid a broader selloff that’s...

Prudential (PRU) Stock Moves -0.67%: What You Should Know By Zacks Investment Research - Jan 20, 2022

In the latest trading session, Prudential (NYSE:PUK) (PRU) closed at $112.43, marking a -0.67% move from the previous day. This change was narrower than the S&P 500's 1.1% loss on the day....

Continue with Apple
Continue with Google
or
Sign up with Email